A Study to Evaluate the Efficacy and Safety of CREZET Tablet

Inclusion Criteria: 1. an adult male and female over 19 years of age 2. A patient with dyslipidemia who is scheduled to administer Crezet tablets according to the medical judgment of the investigator based on permission 3. A person who voluntarily participates in the observational study and agrees in writing to comply with the subject's precautions during the study period after hearing and understanding the detailed explanation of the characteristics of the observational study and the drug to be studied Exclusion Criteria: 1. A person who is prohibited from administering according to the permission of the Crezet definition * Patients who overreact to the principal or component of the Crezet definition * Patients with active liver disease or patients with persistent high symptoms of serum aminotransferase levels * a patient with a muscle disease * a patient administered in combination with a cyclosporine-med * Patients with severe renal failure (Creatinine Clearance (CLcr) \< 30 mL/min) * Women and lactating women who may be pregnant or pregnant * Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption 2. A person who has a history of taking Crezet tablets within three months of the date of registration 3. A person who is deemed inappropriate to participate in this observational study based on the judgment of investigator.